Effect of Disease-Modifying Anti-Rheumatic Drugs on Bone Structure and Strength in Psoriatic Arthritis Patients

Arthritis Research & Therapy
doi 10.1186/s13075-019-1938-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1999English

Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients With Rheumatoid Arthritis?

Neurotherapeutics
NeurologyPharmacology
2019English

OP0281-HPR Preferences of Patients With Rheumatoid Arthritis Regarding Disease Modifying Anti-Rheumatic Drugs: A Discrete Choice Experiment

2018English

Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

PHS30 Health Care Costs in Psoriatic Arthritis (PSA) Patients Newly Initiated on a Biologic Disease-Modifying Anti-Rheumatic Drug (DMARDS) or Methotrexate (MTX)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

AB0490 Evaluation of Inhibitory Factor of Radiographic Progression by Iguratimod Add-On Therapy in Rheumatoid Arthritis Patients With Inadequate Responses to Disease-Modifying Anti-Rheumatic Drugs

2018English

Biological Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis of Polyarticular Course, Enthesitis-Related Arthritis, and Psoriatic Arthritis: A Consensus Statement

2020English

Biological Targets in the Treatment of Rheumatoid Arthritis: A Comprehensive Review of Current and In-Development Biological Disease Modifying Anti-Rheumatic Drugs

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Factors Associated With Quality of Life and Functional Disability Among Rheumatoid Arthritis Patients Treated With Disease-Modifying Anti-Rheumatic Drugs for at Least Six-Months

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy